Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections

Science Translational Medicine

Volumn 7, Issue 300, 2015, Pages

  Taylor, Geraldine ^a   Thom, Michelle ^a   Capone, Stefania ^b   Pierantoni, Angiolo ^b   Guzman, Efrain ^a   Herbert, Rebecca ^a,g   Scarselli, Elisa ^b   Napolitano, Federico ^b   Giuliani, Alessandro ^c   Folgori, Antonella ^b   Colloca, Stefano ^b   Cortese, Riccardo ^d   Nicosia, Alfredo ^b,e,f   Vitelli, Alessandra ^b  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^b ReiThera Srl ^*  (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d Keires AG   (Switzerland)

^e CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BOVINE RESPIRATORY SYNCYTIAL VIRUS INFECTION; CALF (BOVINE); CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RAT; SERODIAGNOSIS; SHAM PROCEDURE; ANIMAL; ANTIBODY SPECIFICITY; BOVINE; BOVINE RESPIRATORY SYNCYTIAL VIRUS; GENE VECTOR; GENETICS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; LUNG; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SECONDARY IMMUNIZATION; SIGMODONTINAE; TREATMENT OUTCOME; VACCINATION; VETERINARY; VIROLOGY;

ANIMALS; ANTIBODY SPECIFICITY; CATTLE; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; LUNG; PRINCIPAL COMPONENT ANALYSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, BOVINE; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGMODONTINAE; TREATMENT OUTCOME; VACCINATION;

EID: 84939434328     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac5757     Document Type: Article

References (47)

1. C. B. Hall, E. A. Simoes, L. J. Anderson, Clinical and epidemiologic features of respiratory syncytial virus. Curr. Top. Microbiol. Immunol. 372, 39-57 (2013).
2. A. Cherukuri, K. Patton, R. A. Gasser Jr., F. Zuo, J. Woo, M. T. Esser, R. S. Tang, Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin. Vaccine Immunol. 20, 239-247 (2013).
3. H. W. Kim, J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, R. H. Parrott, Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-434 (1969).
4. A. Z. Kapikian, R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, C. E. Stewart, An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405-421 (1969).
5. J. L. Hurwitz, Respiratory syncytial virus vaccine development. Expert Rev. Vaccines 10, 1415-1433 (2011).
6. S. Capone, A. M. D'Alise, V. Ammendola, S. Colloca, R. Cortese, A. Nicosia, A. Folgori, Development of chimpanzee adenoviruses as vaccine vectors: Challenges and successes emerging from clinical trials. Expert Rev. Vaccines 12, 379-393 (2013).
7. R. Kohlmann, S. Schwannecke, B. Tippler, N. Ternette, V. V. Temchura, M. Tenbusch, K. Uberla, T. Grunwald, Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J. Virol. 83, 12601-12610 (2009).
8. T. R. Johnson, D. Rangel, B. S. Graham, D. E. Brough, J. G. Gall, Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol. Ther. 22, 196-205 (2014).
9. E. Kim, K. Okada, J. A. Beeler, R. L. Crim, P. A. Piedra, B. E. Gilbert, A. Gambotto, Development of an adenovirus-based respiratory syncytial virus vaccine: Preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J. Virol. 88, 5100-5108 (2014).
10. G. Taylor, Bovine model of respiratory syncytial virus infection. Curr. Top. Microbiol. Immunol. 372, 327-345 (2013).
11. P. Schreiber, J. P. Matheise, F. Dessy, M. Heimann, J. J. Letesson, P. Coppe, A. Collard, High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian white blue calves previously vaccinated with an inactivated BRSV vaccine. J. Vet. Med. B Infect. Dis. Vet. Public Health 47, 535-550 (2000).
12. L. J. Gershwin, E. S. Schelegle, R. A. Gunther, M. L. Anderson, A. R. Woolums, D. R. Larochelle, G. A. Boyle, K. E. Friebertshauser, R. S. Singer, A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 16, 1225-1236 (1998).
13. A. F. Antonis, R. S. Schrijver, F. Daus, P. J. Steverink, N. Stockhofe, E. J. Hensen, J. P. Langedijk, R. G. van der Most, Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: Exploring the parameters of pathogenesis. J. Virol. 77, 12067-12073 (2003).
14. A. Pierantoni, M. L. Esposito, V. Ammendola, F. Napolitano, F. Grazioli, A. Abbate, M. del Sorbo, L. Siani, A. M. D'Alise, A. Taglioni, G. Peretta, A. Siccardi, E. Soprana, M. Panigada, M. Thom, E. Scarselli, A. Folgori, S. Colloca, G. Taylor, R. Cortese, A. Nicosia, S. Capone, A. Vitelli, Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates. Mol. Ther. Methods Clin. Dev. 2, 15018 (2015).
15. E. Barnes, A. Folgori, S. Capone, L. Swadling, S. Aston, A. Kurioka, J. Meyer, R. Huddart, K. Smith, R. Townsend, A. Brown, R. Antrobus, V. Ammendola, M. Naddeo, G. O'Hara, C. Willberg, A. Harrison, F. Grazioli, M. L. Esposito, L. Siani, C. Traboni, Y. Oo, D. Adams, A. Hill, S. Colloca, A. Nicosia, R. Cortese, P. Klenerman, Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 4, 115ra111 (2012).
16. K. J. Ewer,G. A. O'Hara, C. J. Duncan, K. A. Collins, S. H. Sheehy, A. Reyes-Sandoval, A. L. Goodman, N. J. Edwards, S. C. Elias, F. D. Halstead, R. J. Longley, R. Rowland, I. D. Poulton, S. J. Draper, A. M. Blagborough, E. Berrie, S. Moyle, N. Williams, L. Siani, A. Folgori, S. Colloca, R. E. Sinden, A. M. Lawrie, R. Cortese, S. C. Gilbert, A. Nicosia, A. V. Hill, Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 4, 2836 (2013).
17. G. A. Prince, J. J. Mond, D. D. Porter, K. C. Yim, S. J. Lan, D. M. Klinman, Immunoprotective activity and safety of a respiratory syncytial virus vaccine: Mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J. Virol. 77, 13156-13160 (2003).
18. G. Taylor, S. Wyld, J. F. Valarcher, E. Guzman, M. Thom, S. Widdison, U. J. Buchholz, Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves. J. Gen. Virol. 95, 1244-1254 (2014).
19. G. Taylor, L. H. Thomas, E. J. Stott, Effect of vaccination on cell populations in lung washes from calves after infection with respiratory syncytial virus. Res. Vet. Sci. 47, 231-235 (1989).
20. P. S. McNamara, P. Ritson, A. Selby, C. A. Hart, R. L. Smyth, Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch. Dis. Child. 88, 922-926 (2003).
21. A. F. Antonis, M. C. de Jong, W. H. van der Poel, R. G. van der Most, N. Stockhofe-Zurwieden, T. Kimman, R. S. Schrijver, Age-dependent differences in the pathogenesis of bovine respiratory syncytial virus infections related to the development of natural immunocompetence. J. Gen. Virol. 91, 2497-2506 (2010).
22. J. F. Valarcher, J. Furze, S. Wyld, R. Cook, K. K. Conzelmann, G. Taylor, Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J. Virol. 77, 8426-8439 (2003).
23. P. A. Piedra, A. M. Jewell, S. G. Cron, R. L. Atmar, W. P. Glezen, Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: Establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21, 3479-3482 (2003).
24. E. de Barra, S. H. Hodgson, K. J. Ewer, C. M. Bliss, K. Hennigan, A. Collins, E. Berrie, A. M. Lawrie, S. C. Gilbert, A. Nicosia, S. J. McConkey, A. V. Hill, A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLOS One 9, e115161 (2014).
25. J. E. Ledgerwood, A. D. DeZure, D. A. Stanley, L. Novik, M. E. Enama, N. M. Berkowitz, Z. Hu, G. Joshi, A. Ploquin, S. Sitar, I. J. Gordon, S. A. Plummer, L. A. Holman, C. S. Hendel, G. Yamshchikov, F. Roman, A. Nicosia, S. Colloca, R. Cortese, R. T. Bailer, R. M. Schwartz, M. Roederer, J. R. Mascola, R. A. Koup, N. J. Sullivan, B. S. Graham; the VRC 207 Study Team, Chimpanzee adenovirus vector Ebola vaccine-Preliminary report. N. Engl. J. Med. 10.1056/NEJMoa1410863 (2014).
26. S. H. Hodgson, K. J. Ewer, C. M. Bliss, N. J. Edwards, T. Rampling, N. A. Anagnostou, E. de Barra, T. Havelock, G. Bowyer, I. D. Poulton, S. de Cassan, R. Longley, J. J. Illingworth, A. D. Douglas, P. B. Mange, K. A. Collins, R. Roberts, S. Gerry, E. Berrie, S. Moyle, S. Colloca, R. Cortese, R. E. Sinden, S. C. Gilbert, P. Bejon, A. M. Lawrie, A. Nicosia, S. N. Faust, A. V. Hill, Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J. Infect. Dis. 211, 1076-1086 (2014).
27. G. A. Prince, S. J. Curtis, K. C. Yim, D. D. Porter, Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82, 2881-2888 (2001).
28. M. Connors, P. L. Collins, C. Y. Firestone, A. V. Sotnikov, A. Waitze, A. R. Davis, P. P. Hung, R. M. Chanock, B. R. Murphy, Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10, 475-484 (1992).
29. J. S. McLellan, M. Chen, S. Leung, K. W. Graepel, X. Du, Y. Yang, T. Zhou, U. Baxa, E. Yasuda, T. Beaumont, A. Kumar, K. Modjarrad, Z. Zheng, M. Zhao, N. Xia, P. D. Kwong, B. S. Graham, Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
30. W. V. Kalina, A. R. Woolums, R. D. Berghaus, L. J. Gershwin, Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle. Vaccine 22, 1465-1474 (2004).
31. J. E. Doggett, D. Taylor-Robinson, R. G. Gallop, A study of an inhibitor in bovine serum active against respiratory syncytial virus. Arch. Gesamte Virusforsch. 23, 126-137 (1968).
32. G. Taylor, L. H. Thomas, S. G. Wyld, J. Furze, P. Sopp, C. J. Howard, Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves. J. Virol. 69, 6658-6664 (1995).
33. R. M. Gaddum, R. S. Cook, J. M. Furze, S. A. Ellis, G. Taylor, Recognition of bovine respiratory syncytial virus proteins by bovine CD8+ T lymphocytes. Immunology 108, 220-229 (2003).
34. L. Swadling, S. Capone, R. D. Antrobus, A. Brown, R. Richardson, E. W. Newell, J. Halliday, C. Kelly, D. Bowen, J. Fergusson, A. Kurioka, V. Ammendola, M. Del Sorbo, F. Grazioli, M. L. Esposito, L. Siani, C. Traboni, A. Hill, S. Colloca, M. Davis, A. Nicosia, R. Cortese, A. Folgori, P. Klenerman, E. Barnes, A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 6, 261ra153 (2014).
35. S. Sridhar, S. Begom, A. Bermingham, K. Hoschler, W. Adamson, W. Carman, T. Bean, W. Barclay, J. J. Deeks, A. Lalvani, Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305-1312 (2013).
36. T. M. Wilkinson, C. K. Li, C. S. Chui, A. K. Huang, M. Perkins, J. C. Liebner, R. Lambkin-Williams, A. Gilbert, J. Oxford, B. Nicholas, K. J. Staples, T. Dong, D. C. Douek, A. J. McMichael, X. N. Xu, Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274-280 (2012).
37. K. West, L. Petrie, D. M. Haines, C. Konoby, E. G. Clark, K. Martin, J. A. Ellis, The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection in calves. Vaccine 17, 809-820 (1999).
38. G. Taylor, L. H. Thomas, J. M. Furze, R. S. Cook, S. G. Wyld, R. Lerch, R. Hardy, G. W. Wertz, Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions. J. Gen. Virol. 78, 3195-3206 (1997).
39. S. Hgglund, K. Hu, K. Vargmar, L. Por, A. S.Olofson, K. Blodrn, J. Anderson, P. Ahooghalandari, J. Pringle, G. Taylor, J. F. Valarcher, Bovine respiratory syncytial virus ISCOMs-Immunity, protection and safety in young conventional calves. Vaccine 29, 8719-8730 (2011).
40. A. Karger, U. Schmidt, U. J. Buchholz, Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. J. Gen. Virol. 82, 631-640 (2001).
41. H. E. Kennedy, B. V. Jones, E. M. Tucker, N. J. Ford, S. W. Clarke, J. Furze, L. H. Thomas, E. J. Stott, Production and characterization of bovine monoclonal antibodies to respiratory syncytial virus. J. Gen. Virol. 69, 3023-3032 (1988).
42. M. Chen, J. S. Chang, M. Nason, D. Rangel, J. G. Gall, B. S. Graham, J. E. Ledgerwood, A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. J. Immunol. Methods 362, 180-184 (2010).
43. N. D. MacHugh, P. L. Wijngaard, H. C. Clevers, W. C. Davis, Clustering of monoclonal antibodies recognizing different members of the WC1 gene family. Vet. Immunol. Immunopathol. 39, 155-160 (1993).
44. C. J. Howard, P. Sopp, K. R. Parsons, J. Finch, In vivo depletion of BoT4 (CD4) and of non-T4/T8 lymphocyte subsets in cattle with monoclonal antibodies. Eur. J. Immunol. 19, 757-764 (1989).
45. E. A. Lefevre, B. V. Carr, H. Prentice, B. Charleston, A quantitative assessment of primary and secondary immune responses in cattle using a B cell ELISPOT assay. Vet. Res. 40, 3 (2009).
46. R. Benigni, A. Giuliani, Quantitative modeling and biology: The multivariate approach. Am. J. Physiol. 266, R1697-R1704 (1994).
47. P. Jolicoeur, J. E. Mosimann, Size and shape variation in the painted turtle. A principal component analysis. Growth 24, 339-354 (1960).